Efficacy and safety of low molecular weight heparin in renal transplantation
Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low m...
Gespeichert in:
| Veröffentlicht in: | Transplantation 1998-08, Vol.66 (4), p.533-534 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 534 |
|---|---|
| container_issue | 4 |
| container_start_page | 533 |
| container_title | Transplantation |
| container_volume | 66 |
| creator | ALKHUNAIZI, A. M OLYAEI, A. J BARRY, J. M DE MATTOS, A. M CONLIN, M. J LEMMERS, M. J BENNETT, W. M NORMAN, D. J |
| description | Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported.
Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University.
No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal.
Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation. |
| doi_str_mv | 10.1097/00007890-199808270-00020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73891248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16504743</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-d2791bad5f51b9a34dcb41387e303b81c300932b5039a9f93aadca643055ba073</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo67r6E4QcxFt10kma5CiLX7DgRc9lmqZuJf2waVn231uweHV4YWDeh-GdYYwLuBNg9T3MpY2FRFhrwKQaknmSwglbC4UyycDAKVsDSJEIRH3OLmL8mhGFWq_YymqUCmDNdo9VVTtyR05tySNVfjzyruKhO_CmC95NgQZ-8PXnfuR739NQt3zW4FsKfByojX2gdqSx7tpLdlZRiP5q6Rv28fT4vn1Jdm_Pr9uHXdKnWTYmZaqtKKhUlRKFJZSlK6RAoz0CFkY4BLCYFgrQkq0sEpWOMomgVEGgccNuf_f2Q_c9-TjmTR2dD3MQ300x12isSKX5FxSZAqklzuD1Ak5F48u8H-qGhmO-_Gn2bxafoqNQzXe7Ov5hKWqbpQp_AFPSd6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16504743</pqid></control><display><type>article</type><title>Efficacy and safety of low molecular weight heparin in renal transplantation</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>ALKHUNAIZI, A. M ; OLYAEI, A. J ; BARRY, J. M ; DE MATTOS, A. M ; CONLIN, M. J ; LEMMERS, M. J ; BENNETT, W. M ; NORMAN, D. J</creator><creatorcontrib>ALKHUNAIZI, A. M ; OLYAEI, A. J ; BARRY, J. M ; DE MATTOS, A. M ; CONLIN, M. J ; LEMMERS, M. J ; BENNETT, W. M ; NORMAN, D. J</creatorcontrib><description>Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported.
Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University.
No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal.
Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-199808270-00020</identifier><identifier>PMID: 9734500</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Fibrinolytic Agents - therapeutic use ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Kidney Transplantation - adverse effects ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Thrombophlebitis - etiology ; Thrombophlebitis - prevention & control</subject><ispartof>Transplantation, 1998-08, Vol.66 (4), p.533-534</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2379625$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9734500$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ALKHUNAIZI, A. M</creatorcontrib><creatorcontrib>OLYAEI, A. J</creatorcontrib><creatorcontrib>BARRY, J. M</creatorcontrib><creatorcontrib>DE MATTOS, A. M</creatorcontrib><creatorcontrib>CONLIN, M. J</creatorcontrib><creatorcontrib>LEMMERS, M. J</creatorcontrib><creatorcontrib>BENNETT, W. M</creatorcontrib><creatorcontrib>NORMAN, D. J</creatorcontrib><title>Efficacy and safety of low molecular weight heparin in renal transplantation</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported.
Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University.
No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal.
Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Thrombophlebitis - etiology</subject><subject>Thrombophlebitis - prevention & control</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMo67r6E4QcxFt10kma5CiLX7DgRc9lmqZuJf2waVn231uweHV4YWDeh-GdYYwLuBNg9T3MpY2FRFhrwKQaknmSwglbC4UyycDAKVsDSJEIRH3OLmL8mhGFWq_YymqUCmDNdo9VVTtyR05tySNVfjzyruKhO_CmC95NgQZ-8PXnfuR739NQt3zW4FsKfByojX2gdqSx7tpLdlZRiP5q6Rv28fT4vn1Jdm_Pr9uHXdKnWTYmZaqtKKhUlRKFJZSlK6RAoz0CFkY4BLCYFgrQkq0sEpWOMomgVEGgccNuf_f2Q_c9-TjmTR2dD3MQ300x12isSKX5FxSZAqklzuD1Ak5F48u8H-qGhmO-_Gn2bxafoqNQzXe7Ov5hKWqbpQp_AFPSd6E</recordid><startdate>19980827</startdate><enddate>19980827</enddate><creator>ALKHUNAIZI, A. M</creator><creator>OLYAEI, A. J</creator><creator>BARRY, J. M</creator><creator>DE MATTOS, A. M</creator><creator>CONLIN, M. J</creator><creator>LEMMERS, M. J</creator><creator>BENNETT, W. M</creator><creator>NORMAN, D. J</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19980827</creationdate><title>Efficacy and safety of low molecular weight heparin in renal transplantation</title><author>ALKHUNAIZI, A. M ; OLYAEI, A. J ; BARRY, J. M ; DE MATTOS, A. M ; CONLIN, M. J ; LEMMERS, M. J ; BENNETT, W. M ; NORMAN, D. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-d2791bad5f51b9a34dcb41387e303b81c300932b5039a9f93aadca643055ba073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Thrombophlebitis - etiology</topic><topic>Thrombophlebitis - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ALKHUNAIZI, A. M</creatorcontrib><creatorcontrib>OLYAEI, A. J</creatorcontrib><creatorcontrib>BARRY, J. M</creatorcontrib><creatorcontrib>DE MATTOS, A. M</creatorcontrib><creatorcontrib>CONLIN, M. J</creatorcontrib><creatorcontrib>LEMMERS, M. J</creatorcontrib><creatorcontrib>BENNETT, W. M</creatorcontrib><creatorcontrib>NORMAN, D. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ALKHUNAIZI, A. M</au><au>OLYAEI, A. J</au><au>BARRY, J. M</au><au>DE MATTOS, A. M</au><au>CONLIN, M. J</au><au>LEMMERS, M. J</au><au>BENNETT, W. M</au><au>NORMAN, D. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of low molecular weight heparin in renal transplantation</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1998-08-27</date><risdate>1998</risdate><volume>66</volume><issue>4</issue><spage>533</spage><epage>534</epage><pages>533-534</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported.
Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University.
No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal.
Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>9734500</pmid><doi>10.1097/00007890-199808270-00020</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 1998-08, Vol.66 (4), p.533-534 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73891248 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Adolescent Adult Aged Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Fibrinolytic Agents - therapeutic use Heparin, Low-Molecular-Weight - therapeutic use Humans Kidney Transplantation - adverse effects Medical sciences Middle Aged Pharmacology. Drug treatments Thrombophlebitis - etiology Thrombophlebitis - prevention & control |
| title | Efficacy and safety of low molecular weight heparin in renal transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A32%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20low%20molecular%20weight%20heparin%20in%20renal%20transplantation&rft.jtitle=Transplantation&rft.au=ALKHUNAIZI,%20A.%20M&rft.date=1998-08-27&rft.volume=66&rft.issue=4&rft.spage=533&rft.epage=534&rft.pages=533-534&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-199808270-00020&rft_dat=%3Cproquest_pubme%3E16504743%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16504743&rft_id=info:pmid/9734500&rfr_iscdi=true |